Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus METAHYDRIN.
ENDURONYL FORTE vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic